The Latest Breaking News from FDA

A massive recall is getting most of the blame for the U.S. baby formula shortage, but experts say the products have long been vulnerable to this type of crisis

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT

Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.

CHICAGO — With the U.S. Supreme Court poised to overturn Roe v. Wade, Planned Parenthood of Illinois said Monday it has begun offering abortion pills by mail for state residents who qualify.

The U.S.

The recall includes nearly 50 products

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial.  Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

Late last week, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced that Bayer AG (OTC:BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The enrollment was paused in the Phase 1 trial of ATA2271 for mesothelioma after a patient death. The move followed a strategic review and asset-level prioritization.…

Parents hoping to get their youngest children vaccinated against COVID-19 have some encouraging news